Brodalumab demonstrates significant clinical response in psoriatic arthritis

Data suggest blocking IL-17 a beneficial new strategy

2013-06-12

(Press-News.org) Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA).

PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in up to 30% of those of cases.3

IL-17 induces production of anti-microbial peptides and pro-inflammatory cytokines that in turn may help sustain immune responses in the skin.4 With similar pathways impacting skin and joint diseases, data suggest that cytokine-targeting strategies aimed at blocking signalling through the IL-17 receptor may be a beneficial new strategy in the treatment of PsA.

Lead author of the study Dr Mease, Swedish Medical Center and University of Washington, Seattle, US commented "PsA is a progressive disease associated with a number of co-morbidities, disability and disfigurement. There is a need for therapies to better manage patient outcomes, and prevent long-term bone loss and permanent joint damage, especially in those patients for whom anti-TNF therapy is not effective or tolerated." Dr Mease continued, "these significant patient responses support continued evaluation of brodalumab for the treatment of PsA and clearly show that cytokine-targeting strategies aimed at blocking signalling through the IL-17 receptor may represent an important new treatment strategy."

The study involving 168 patients with at least a 6 month history of PsA demonstrated that 37% and 39% of subjects in the 140- and 280-mg brodalumab groups respectively, achieved the primary endpoint of ACR20* response rates at week 12 compared with 18% of subjects in the placebo group (p END

ELSE PRESS RELEASES FROM THIS DATE:

'Fast track' approach to giant cell arteritis significantly reduces risk of blindness

2013-06-12

Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that rapid evaluation for Giant Cell Arteritis (GCA) by Color Doppler Ultrasound (CDUS) followed by immediate initiation of treatment (if required) significantly reduces permanent vision loss. Of the patients evaluated by the ''fast track'' principle from March 2010 to December 2012, 11.1% had transient visual manifestations, and none went on to suffer from permanent visual loss. GCA is a condition in which medium and large-size arteries, ...

CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis

2013-06-12

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA). Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels ...

Abatacept as effective as adalimumab in rheumatoid arthritis

2013-06-12

Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA). AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial. RA is a ...

Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis

2013-06-12

Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile. Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory ...

New method successfully scores joint damage in rheumatoid arthritis

2013-06-12

Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA. The study validated the use of ARASHI to assess joint damage in RA, and clarified the pattern of progression of damage during two-year TNF-blocking therapies. In addition to concluding the success of the scoring method, the data also showed that hip and knee joints with pre-existing damage were predisposed to continue destruction, even during ...

RA patients define ideal online tool for physical activity

2013-06-12

Madrid, Spain, 12 June 2013: Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism. These data show that seven categories are crucial for the adoption and maintenance of PA: personal incentives, personal mastering, information adapted to the Rheumatoid Arthritis (RA) condition, peer support, professional coaching, physical environment and resources, and societal support/financial assistance. RA is a chronic autoimmune ...

Swiss ball improves muscle strength and walking performance in ankylosing spondylitis

2013-06-12

Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates that progressive muscle strengthening using a Swiss ball is effective in improving muscle strength and walking performance in patients with Ankylosing Spondylitis (AS). Patients randomised to the exercise programme showed statistically significant improvements in muscle strength with no worsening of disease activity; in addition these patients reported greater satisfaction with their treatment than those in the control group. AS ...

Study assesses impact of rheumatoid arthritis on joint replacement surgery outcomes

2013-06-12

Two new studies by researchers at Hospital for Special Surgery have shed light on joint replacement outcomes in patients with rheumatoid arthritis (RA). One study overturns the common belief that RA patients have worse outcomes after a total knee replacement (TKR) than patients who undergo the operation for osteoarthritis. The other study demonstrates that RA patients who undergo a total hip replacement were as likely to have significant improvements in function and pain as patients with osteoarthritis (OA), even though they did not do as well. The news will be reported ...

New additive offers near-perfect results as nucleating agent for organic semiconductors

2013-06-12

(Santa Barbara, Calif.) — Pixie dust may be the stuff of fanciful fiction, but for scientists at UC Santa Barbara's Department of Materials, a commonly used sugar-based additive has been found to have properties that are near magical. By adding minute amounts of it during the fabrication of organic semiconductors, they have been able to dramatically increase yield and control crystallization, which could, in the near future, make the technology not only cheaper and more accessible, but also enhance its performance. Results of their study are published in the recent issue ...

Vitamin C may be beneficial against exercise-induced bronchoconstriction

2013-06-12

Vitamin C may substantially reduce bronchoconstriction caused by exercise, says Dr. Harri Hemila from the University of Helsinki, Finland. Hemila's meta-analysis "Vitamin C may alleviate exercise-induced bronchoconstriction" was published in BMJ Open (7 June, 2013) Exercise-induced bronchoconstriction means the transient narrowing of the airways that occurs during or after exercise. It can cause symptoms such as cough, wheezing and the shortness of breath. Formerly, this condition was called exercise-induced asthma. Usually, the diagnosis of exercise-induced bronchoconstriction ...

Brodalumab demonstrates significant clinical response in psoriatic arthritis

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: